Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed,Inapplicable
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Recipient : MaxCyte
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Walking Fish will use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to engineer novel B-cell based medicines for the treatment of serious diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 05, 2023
Lead Product(s) : Undisclosed,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Recipient : MaxCyte
Deal Size : Undisclosed
Deal Type : Licensing Agreement